New drug targets genetic weakness in Hard-to-Treat cancers
NCT ID NCT04520269
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called pacritinib in people with advanced solid tumors (like breast cancer) that have a specific genetic change called 1q21.3 amplification. The goal is to see if the drug can shrink tumors or slow their growth. About 74 adults whose cancer has not responded to standard treatments will take part. The drug is taken by mouth and aims to block a protein linked to cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National University Hospital
Singapore, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple